Pfizer Buys $50M Stake in Perlegen; 12-Percent Ownership Could Grow If IPO Launched

Dec 27, 2005

NEW YORK, Dec. 27 (GenomeWeb News) - Pharmaceutical giant Pfizer invested $50 million in Perlegen Sciences, the private biotechnology company disclosed today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Bio-Rad Shutters Former GnuBio Facility as Part of Digital Biology R&D Consolidation
NIH Aims to Ease Access to Genomic Summary Results
DxTerity, City of Hope Partner to Develop Blood Test for Radiation Therapy Response
Ancient African Genomes Offer Peek at Continent's Population Histories Over 8,000 Years
Cellular Dynamics International, Nanion Technologies Ink Comarketing Pact
UgenTec, R-Biopharm Collaborate to Develop Software for Automated PCR Analysis

The Scan

An Expensive Deal

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Figuring Out Who It'll Work For

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

Ye Old P-Value

Nature News writes that researchers are still wrangling over the role of the p-value.

Main menu